Longitudinal Registry Including Patients Treated With Heavy Particles
Launched by CNAO NATIONAL CENTER OF ONCOLOGICAL HADRONTHERAPY · Jan 10, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is a registry study designed to gather information about patients with cancer who have been treated using a special type of radiation therapy known as particle therapy, which includes protons and carbon ions. The goal is to collect both past and current data from patients treated at the National Center for Oncological Hadrontherapy (CNAO) in Pavia. By tracking these patients, the researchers hope to learn more about how effective this treatment is and how it affects patients over time.
To participate in this trial, patients must have received heavy particle therapy at the CNAO and should be able to understand and agree to participate by signing a consent form. All ages and genders are welcome to join, but those who cannot understand the consent form will not be included. Participants can expect to contribute to important research that may improve cancer treatment in the future, as their experiences will help researchers evaluate the outcomes of particle therapy and its potential side effects.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients treated with heavy particles at Fondazione CNAO, Pavia
- • Patients who have the ability to understand and be willing to sign a written informed consent document
- Exclusion Criteria:
- • Patients or legal guardians who are unable to understand informed consent document
About Cnao National Center Of Oncological Hadrontherapy
CNAO (National Center of Oncological Hadrontherapy) is a leading research institution dedicated to advancing cancer treatment through innovative hadrontherapy techniques. Located in Pavia, Italy, CNAO focuses on the clinical application of proton and heavy ion therapies, offering state-of-the-art facilities and expertise for the treatment of various malignancies. Committed to enhancing patient outcomes, CNAO engages in rigorous clinical trials and collaborative research initiatives aimed at improving therapeutic strategies, optimizing treatment protocols, and contributing to the global body of knowledge in oncological care. Through its multidisciplinary approach, CNAO strives to provide personalized, effective cancer therapies while prioritizing patient safety and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pavia, , Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials